Clinical TrialJul 15, 2026, 08:01 AM
MediciNova Achieves Full Enrollment in SEANOBI-ALS Study for MN-166
AI Summary
MediciNova, Inc. announced the successful achievement of target enrollment, with 200 patients, in its NIH-funded SEANOBI-ALS study evaluating MN-166 (ibudilast) for amyotrophic lateral sclerosis (ALS). This Expanded Access Program provides the investigational drug to ALS patients not eligible for other trials. Final patient follow-ups are expected to conclude in early 2027, after which data analysis will commence for scientific presentations and publications. The company previously completed enrollment for its COMBAT-ALS Phase 2b/3 clinical trial of MN-166 in September 2025.
Key Highlights
- Target enrollment of 200 patients achieved in SEANOBI-ALS study.
- SEANOBI-ALS study evaluates MN-166 (ibudilast) in patients with ALS.
- The study is funded by the NIH under the ACT for ALS program.
- Final patient follow-ups are projected to conclude in early 2027.
- Data analysis phase will follow to support scientific presentations.
- MediciNova completed enrollment for COMBAT-ALS Phase 2b/3 trial in September 2025.
Price Impact
More from MNOV